• Explore /
  • Poster
  • / PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.

PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.

Abstract Poster

Authors

Pier Conte

Pier Franco Conte

Department of Surgery, Oncology and Gastroenterology, University of Padova, Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy

Pier Franco Conte , Gaia Griguolo , Maria Vittoria Dieci , Giancarlo Bisagni , Alba Ariela Brandes , Antonio Frassoldati , Luigi Cavanna , Antonino Musolino , Francesco Giotta , Anita Rimanti , Ornella Garrone , Patricia Galvan , Fara Brasó Maristany , Enrico Orvieto , Loredana Urso , Antonino Maiorana , Sara Balduzzi , Roberto D'Amico , Valentina Guarneri , Aleix Prat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT00629278

Citation

J Clin Oncol 37, 2019 (suppl; abstr 544)

DOI

10.1200/JCO.2019.37.15_suppl.544

Abstract #

544

Poster Bd #

36

Abstract Disclosures

Similar Posters

First Author: Maria Vidal

First Author: Gaia Griguolo

First Author: Pamela N. Munster

First Author: Beverly Moy